Document is current
Any future updates will be listed below
-
Authors
Lebwohl, Mark
Deodhar, Atul
Schwartzman, Sergio
Salvarani, Carlo
Feely McDonald, Meghan
Bello, Natalia
Grace, Elsie L.
Inman, Elsa
Kronbergs, Andris
Ngantcha, Marcus
Rahman, Proton
Papp, Kim A.
Merola, Joseph F.
Gottlieb, Alice B.
Blauvelt, Andrew
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 2 October 2024
Accepted: 5 December 2024
First Online: 22 January 2025
Declarations
:
: Mark Lebwohl has received grants/contracts from: Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio, Dermavant Sciences, Eli Lilly and Company, Incyte, Inozyme, Janssen, Pfizer, Sanofi Regeneron, and UCB; has received honoraria as a consultant for: Almirall, AltruBio Inc., Apogee, Arcutis, AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dermsquared, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Atul Deodhar has served as a consultant and/or on the advisory board for: Bristol Myers Squibb, Eli Lilly and Company, Janssen, MoonLake, Novartis, Pfizer, and UCB Pharma; and has received research grants from: Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma. Sergio Schwartzman has received grants and/or contracts from: Eli Lilly and Company; serves on the National Psoriasis Foundation Medical Board; is part of the scientific advisory board at: Myriad Genetics; and is a consultant for: AbbVie, Eli Lilly and Company, Janssen, Jubilant Pharma, Myriad Genetics, Novartis, Regeneron, Sanofi, Stelexis Therapeutics, Teijin Pharma, and UCB Pharma. Carlo Salvarani has served as a consultant for: AbbVie, Eli Lilly and Company, and Roche; and has received grant/research support from: Roche. Meghan Feely McDonald is associate staff at Mount Sinai Hospital, Mount Sinai West, and Mount Sinai Morningside; was an employee of Eli Lilly and Company at the time of this manuscript development; has received consulting, travel, or speaker fees from: American Academy of Dermatology, Aerolase, Castle Biosciences, CeraVe—L’Oréal, DREAM USA, Galderma Aesthetics, Glow Recipe, La Roche-Posay—L’Oréal, Revian, Sonoma Pharmaceuticals, Sun Pharma, and Suneva Medical. Natalia Bello, Elsie L. Grace, Elsa Inman, Andris Kronbergs, and Marcus Ngantcha are employees and shareholders of Eli Lilly and Company. Proton Rahman has received grants/contracts from: Janssen and Novartis; and has received honoraria as a consultant for: AbbVie, Eli Lilly and Company, Janssen, Novartis, and Pfizer. Kim A. Papp has served as a consultant, speaker, scientific officer, steering committee member, and/or advisory board member for: AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Janssen, Kymab, Kyowa Hakko Kirin, LEO, Lilly, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB, and Zai Lab. Joseph F. Merola is a consultant and/or investigator for: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Regeneron, Sun Pharma, and UCB Pharma. Alice B. Gottlieb receives research/educational grants from Highlights Therapeutics, Bristol Myers Squibb, Janssen, and UCB Pharma (all paid to Mount Sinai School of Medicine); she has received honoraria as an advisory board member and consultant for Amgen, AnaptypsBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Eli Lilly and Company, Highlights Therapeutics, Janssen, Novartis, Sanofi, Teva, UCB Pharma, and Xbiotech (stock options for RA). Andrew Blauvelt has served as a speaker (received honoraria) for Eli Lilly and Company and UCB, has served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Celldex, Celltrion, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Oruka, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor, has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, UCB Pharma, and Ventyx, and owns stock in Lipidio and Oruka.
: The protocols for all studies included in this analysis were approved by the ethics committee or institutional review board at each participating site. All studies were conducted in accordance with the ethical principles of the Declaration of Helsinki. Eligible patients provided written informed consent before initiating any study-related procedures.
